InnoCare Pharma’s HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority of Singapore for treating adult patients with relapsed or refractory marginal zone lymphoma. Orelabrutinib is a highly selective BTK inhibitor developed for cancer and autoimmune diseases, offering a new treatment option for patients in Singapore. The drug has also been approved in China for various indications, including chronic lymphocytic leukemia and mantle cell lymphoma, and is included in China’s National Reimbursement Drug List. InnoCare is a biopharmaceutical company focused on developing innovative treatments for cancer and autoimmune diseases globally.

Read more at GlobeNewswire: InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for